230 related articles for article (PubMed ID: 23723314)
1. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
2. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.
Akaza H; Kim CS; Carroll P; Choi IY; Chung BH; Cooperberg MR; Hirao Y; Hinotsu S; Horie S; Lee JY; Namiki M; Ng CF; Onozawa M; Ozono S; Ueno S; Umbas R; Ye D; Zhu G
Prostate Int; 2014; 2(2):50-69. PubMed ID: 26153555
[TBL] [Abstract][Full Text] [Related]
3. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management.
Akaza H; Carroll P; Cooperberg MR; Hinotsu S
Jpn J Clin Oncol; 2012 Mar; 42(3):226-36. PubMed ID: 22217576
[TBL] [Abstract][Full Text] [Related]
4. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
8. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
9. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
10. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
11. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Carlsson S; Roobol MJ; Schröder FH; Hugosson J; Auvinen A
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24771874
[No Abstract] [Full Text] [Related]
12. Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Walsh PC
J Natl Cancer Inst; 2014 Feb; 106(2):djt432. PubMed ID: 24399847
[No Abstract] [Full Text] [Related]
13. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.
Yamaguchi Y; Hayashi Y; Ishizuya Y; Takeda K; Nakai Y; Arai Y; Nakayama M; Kakimoto K; Nishimura K
Jpn J Clin Oncol; 2015 Feb; 45(2):197-201. PubMed ID: 25381383
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
16. Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.
Carter HB
Eur Urol; 2014 Dec; 66(6):973-4. PubMed ID: 25018035
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening: biases and the need for consensus.
Brawley OW
J Natl Cancer Inst; 2013 Oct; 105(20):1522-4. PubMed ID: 24092919
[No Abstract] [Full Text] [Related]
18. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
19. Response.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2014 Feb; 106(2):djt433. PubMed ID: 24399848
[No Abstract] [Full Text] [Related]
20. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
Akaza H; Hinotsu S; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Hirao Y; Murai M; Yamanaka H; Namiki M
J Urol; 2006 Dec; 176(6 Pt 2):S47-9. PubMed ID: 17084166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
